N Hollander
Overview
Explore the profile of N Hollander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Minai-Fleminger Y, Gangwar R, Migalovich-Sheikhet H, Seaf M, Leibovici V, Hollander N, et al.
Clin Exp Allergy
. 2014 Sep;
44(11):1335-46.
PMID: 25255823
Background: Allergy is characterized by eosinophilia and an increased susceptibility to microbial infection. Atopic dermatitis (AD) is typically associated with Staphylococcus aureus (SA) colonization. Some of the mechanisms by which...
2.
Manzur S, Cohen S, Haimovich J, Hollander N
Clin Exp Immunol
. 2012 Nov;
170(3):291-9.
PMID: 23121670
The present standard of care for B cell non-Hodgkin's lymphoma includes the anti-CD20 monoclonal antibody rituximab. Although combination treatments with chemotherapy and rituximab improved the duration of remissions and overall...
3.
Ford-Jones E, Kitai I, Corey M, Notenboom R, Hollander N, Kelly E, et al.
Can J Infect Dis
. 2012 Apr;
7(5):326-8.
PMID: 22514458
Objective: To determine the prevalence of infection with toxoplasmosis by country of birth and age in a sample of convenience. Design: Banked sera and the computerized data base of demographic...
4.
Hollander N, Augustin N, Sauerbrei W
Methods Inf Med
. 2006 Feb;
45(1):44-50.
PMID: 16482369
Objectives: We illustrate a recently proposed two-step bootstrap model averaging (bootstrap MA) approach to cope with model selection uncertainty. The predictive performance is investigated in an example and in a...
5.
Mross K, Hollander N, Unger C, Massing U
Int J Clin Pharmacol Ther
. 2005 Dec;
43(12):601-2.
PMID: 16372534
No abstract available.
6.
Benaroya-Milshtein N, Hollander N, Apter A, Kukulansky T, Raz N, Wilf A, et al.
Eur J Neurosci
. 2004 Sep;
20(5):1341-7.
PMID: 15341605
The importance of environment in the regulation of brain, behaviour and physiology has long been recognized in biological, social and medical sciences. Animals maintained under enriched conditions have clearly been...
7.
Mross K, Haring B, Hollander N, Mielke S, Behringer D, Massing U, et al.
Onkologie
. 2003 Feb;
25(6):503-8.
PMID: 12566894
Purpose: Aim of this study was to characterize the difference in pharmacokinetics (PK) of paclitaxel (PAC) after 1-h and 3-h infusion in humans and to define a pharmacodynamic relationship between...
8.
Hollander N, Schumacher M
Onkologie
. 2001 Jul;
24(2):194-9.
PMID: 11441304
The identification and assessment of prognostic factors is an important task in clinical cancer research. Quantitative prognostic factors are often categorized by using one or several cutpoints to obtain an...
9.
Aviram R, Raz N, Kukulansky T, Hollander N
Cancer Immunol Immunother
. 2001 Jun;
50(2):61-8.
PMID: 11401026
The homing receptor L-selectin is essential for the migration of naive lymphocytes into peripheral lymph nodes. In contrast to naive lymphocytes, activated and memory cells down-regulate L-selectin and enter peripheral...
10.
Mross K, Hollander N, Hauns B, Schumacher M, Maier-Lenz H
Cancer Chemother Pharmacol
. 2000 Jun;
45(6):463-70.
PMID: 10854133
Purpose: To characterize the disposition of paclitaxel (PAC) after a 1-h infusion in humans and define if possible a pharmacodynamic relationship between PAC disposition and the observed toxicity. Patients And...